This compares to a net loss of $9,800,000 for the same period in 2022, which included a 4.6 $1,000,000 noncash loss related to Angel Pharmaceuticals. The net loss for the full year 2023 was $27,000,000 including a $5,300,000 noncash loss related to Angel compared to a net a net loss of $41,300,000 including a $10,000,000 noncash loss related to Angel for the full year 2022. Total stock compensation expense for the Q4 and full year 2023 was $600,000 $2,100,000 respectively, compared to $600,000 $2,700,000 in the same periods in 2022. As of December 31, 2020 3, Corbus had cash, cash equivalents and marketable securities totaling $27,100,000 as compared to $42,300,000 at December 31, 2022. I will now turn the call over to Richard, who will discuss our clinical progress and elaborate on our strategy and plans.